CLDX Earnings

CLDX reported its earnings on 2025-11-05, showcasing a revenue of 0.00 against an estimate of 2.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.88 by 0% . The stock experienced a -1.98% price change on the earnings day and a 2.7% change over the next five days, reflecting market reactions to the results.

Following CLDX's earnings announcement on 2025-11-05, the stock price moved by -1.98% on the day of the release. Over the subsequent five days, it saw a 2.70% change. Historically, CLDX's stock price tends to shift by an average of -1.48% in the 10 days leading up to earnings and -0.82% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CLDX’s annual revenue to reach 2.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -20.67% and EPS estimates Revise Upward by 15.79% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CLDX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -20.67%, while EPS estimates moved Revise Upward by 15.79% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CLDX's stock price typically moves by -1.48% in the 10 days before its earnings and -0.82% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 2.00M.

The earnings call indicates a mixed outlook. Positive aspects include a strong cash position, successful Phase 1 study results, and high response rates in clinical trials. However, challenges in patient recruitment, potential safety concerns, and competitive market risks temper enthusiasm. The Q&A revealed cautious optimism but highlighted unresolved issues, such as patient recruitment challenges and management's vague responses. The market cap suggests moderate volatility, leading to a neutral short-term stock price prediction.